LIGHT THE WAY
- Manufacturer
- mybody
- Effective date
- 2012-05-02
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 5
- Source
- full-release
- Hydrated at
- 2026-05-31 22:31:36
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
ACTIVE INGREDIENT HYDROQUINONE 2%
OTC - PURPOSE SECTION
PURPOSE SKIN LIGHTENING
INDICATIONS & USAGE SECTION
USE GRADUALLY AND EFFECTIVELY LIGHTENS DARK AREAS IN THE SKIN
WARNINGS SECTION
WARNINGS
FOR EXTERNAL USE ONLY
OTC - DO NOT USE SECTION
DO NOT USE
- ON INFLAMED OR BROKEN SKIN.
- FOR THE PREVENTION OF SUNBURN.
- AS A SUNSCREEN.
OTC - ASK DOCTOR SECTION
ASK A DOCTOR OR PHARMACIST BEFORE USE IF
- PREGNANT OR LACTATING.
- IN COMBINATION WITH PRODUCTS CONTAINING RESORCINOL, PHENOL, OR SALICYLIC ACID.
- BY CHILDREN UNDER THE AGE OF 12.
OTC - STOP USE SECTION
STOP USE AND ASK A DOCTOR
- IF AREAS DARKEN OR BLUE-BLACK DARKENING OCCURS.
- MILD IRRITATION MAY OCCUR. IF IRRITATION BECOMES SEVERE, STOP USE AND CONSULT A DOCTOR.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN * IF SWALLOWED, GET MEDICAL HELP OR CONTACT A POISON CONTROL CENTER RIGHT AWAY.
DOSAGE & ADMINISTRATION SECTION
DIRECTIONS
- ADULTS ONLY
- PM: APPLY SIDE 1 HYDROQUINONE TO CLEAN SKIN. ALLOW TO DRY. NEXT APPLY SIDE 2 WITH RETINOL. ALLOW TO DRY. DAILY USE OF SUNSCREEN IS RECOMMENDED.
- FOR BEST RESULTS: APPLY MYBODY'S PROTECT AND SERVE SUN SHIELD SPF 30 (AM ONLY) WHEN USING LIGHT THE WAY.
- FOR SENSITIVE SKIN, TEST OVERNIGHT ON SMALL AREA (INSIDE ELBOW).
- IF NO IMPROVEMENT IS SEEN AFTER 3 MONTHS, DISCONTINUE USE. ON VERY DARK SKIN, LIGHTENING EFFECT MAY NOT BE NOTICEABLE.
- TO PREVENT DARKENING FROM REOCCURRING, USE A SUNSCREEN OR WEAR PROTECTIVE CLOTHING TO COVER TREATED SKIN DURING AND AFTER PRODUCT USE.
OTHER SAFETY INFORMATION
OTHER INFORMATION
* AVOID STORAGE AT EXTREME TEMPERATURES (BELOW 40°F AND ABOVE 100°F).
INACTIVE INGREDIENT SECTION
INACTIVE INGREDIENTS CHAMBER A: WATER, HEXYL LAURATE, GLYCERYL STEARATE SE, CETYL ALCOHOL, CAPRYLIC/CAPRIC TRIGLYCERIDE, STEARIC ACID, BUTYROSPERMUM PARKII (SHEA BUTTER), GLYCERIN, CETETH-2, BEHENYL ALCOHOL, HYDROXYPROPYL STARCH PHOSPHATE, XANTHAN GUM, POTASSIUM HYDROXIDE, SODIUM SULFITE, FRAGRANCE, CAPRYLYL GLYCOL, PHENOXYETHANOL, CITRIC ACID, SODIUM METABISULFITE.
OTC - QUESTIONS SECTION
QUESTIONS OR COMMENTS?
CALL 877.423.1314 *
WWW.LOVEMYBODY.COM
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
OTC - WHEN USING SECTION
WHEN USING THIS PRODUCT
- AVOID CONTACT WITH EYES.
- LIMIT SUN EXPOSURE.
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| HYDROQUINONE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 85490a6b-2306-6bf2-c51b-eb63537dc2da | Product name | 1 | 20140508 |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 49520-201-51 | 2019-11-13 | C162847 | 48780-1 | 97449f38-c6fb-f6ea-e053-dbdaa90aa703 | LIGHT THE WAY |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49520-201-11 | LIGHT THE WAY | 15 mL in 1 BOTTLE | LOTION | 15 | 5 | |
| 49520-201-51 | LIGHT THE WAY | 1 in 1 BOX | LOTION | 1 | 5 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| HYDROQUINONE | ACTIVE INGREDIENT | XV74C1N1AE | 5 | |
| HYDROQUINONE | ACTIVE MOIETY | XV74C1N1AE | 5 | |
| CAPRYLYL GLYCOL | INACTIVE INGREDIENT | 00YIU5438U | 5 | |
| CETETH-2 | INACTIVE INGREDIENT | 7H8VAM7778 | 5 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 5 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 5 | |
| DOCOSANOL | INACTIVE INGREDIENT | 9G1OE216XY | 5 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 5 | |
| GLYCERYL STEARATE SE | INACTIVE INGREDIENT | FCZ5MH785I | 5 | |
| HEXYL LAURATE | INACTIVE INGREDIENT | 4CG9F9W01Q | 5 | |
| HYDROXYPROPYL CORN STARCH (5% SUBSTITUTION BY WEIGHT) | INACTIVE INGREDIENT | 9M44R3409A | 5 | |
| MEDIUM-CHAIN TRIGLYCERIDES | INACTIVE INGREDIENT | C9H2L21V7U | 5 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 5 | |
| POTASSIUM HYDROXIDE | INACTIVE INGREDIENT | WZH3C48M4T | 5 | |
| SHEA BUTTER | INACTIVE INGREDIENT | K49155WL9Y | 5 | |
| SODIUM METABISULFITE | INACTIVE INGREDIENT | 4VON5FNS3C | 5 | |
| SODIUM SULFITE | INACTIVE INGREDIENT | VTK01UQK3G | 5 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 5 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 5 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 5 |
Products#
Every source-derived product name is available through these pages.
- LIGHT THE WAY
- HYDROQUINONE
- WATER
- HEXYL LAURATE
- GLYCERYL STEARATE SE
- CETYL ALCOHOL
- MEDIUM-CHAIN TRIGLYCERIDES
- STEARIC ACID
- SHEA BUTTER
- GLYCERIN
- CETETH-2
- DOCOSANOL
- HYDROXYPROPYL CORN STARCH (5% SUBSTITUTION BY WEIGHT)
- XANTHAN GUM
- POTASSIUM HYDROXIDE
- SODIUM SULFITE
- CAPRYLYL GLYCOL
- PHENOXYETHANOL
- CITRIC ACID MONOHYDRATE
- SODIUM METABISULFITE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 49520-201 | 49520-201-11, 49520-201-51 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | CREAM / VAGINAL | 3 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, ORALLY DISINTEGRATING / ORAL | 0.15 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | TABLET / ORAL | 8 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | LOTION / TOPICAL | 0.2 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION / SUBMUCOSAL | 5 %w/v | ||
| SODIUM SULFITE | SODIUM SULFITE | VTK01UQK3G | INJECTION / SUBCUTANEOUS | 0.15 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAMUSCULAR | 28 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | CREAM / TOPICAL | 46 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, COATED / ORAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / EPIDURAL | 0.02 %w/v | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | CAPSULE, EXTENDED RELEASE / ORAL | 64 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAVENOUS | 2068 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | AEROSOL, FOAM / TOPICAL | 10.87 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 120 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE, EXTENDED RELEASE / ORAL | 101 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | CREAM, AUGMENTED / TOPICAL | 10 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / BUCCAL | 6 mg | ||
| SODIUM SULFITE | SODIUM SULFITE | VTK01UQK3G | INJECTION, SOLUTION / INTRAMUSCULAR | 2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRAMUSCULAR | 27.5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 0.15 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYRUP / ORAL | 722 mg/5ml | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | EMULSION / ORAL | NA | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | IMPLANT / SUBCUTANEOUS | 1.04 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / RECTAL | 17 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / TOPICAL | 8 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / PERINEURAL | 0.05 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / RESPIRATORY (INHALATION) | 0.03 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GRANULE, FOR SUSPENSION / ORAL | 113 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SUSPENSION / OPHTHALMIC | 0.5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / OPHTHALMIC | 3 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, EXTENDED RELEASE / ORAL | 528 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / IRRIGATION | 1 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / SUBLINGUAL | 9 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRAVENOUS | 27.5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | TABLET, CHEWABLE / ORAL | 0.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | INJECTION / INTRAVENOUS | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / ORAL | 315 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY, METERED / NASAL | 2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAVENOUS | 10 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 59 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / ORAL | 269 mg | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE / ORAL | 172 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 0.6 %w/w |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f4775a0b-f209-4591-9d3b-c84c95d6be5c | 508d4c37-c846-4b5f-871a-09b7c963f477 | 2012-05-02 | Warnings | f4775a0b-f209-4591-9d3b-c84c95d6be5c 508d4c37-c846-4b5f-871a-09b7c963f477 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.


